Adam L. Boxer

37.7k total citations · 7 hit papers
213 papers, 11.4k citations indexed

About

Adam L. Boxer is a scholar working on Neurology, Physiology and Psychiatry and Mental health. According to data from OpenAlex, Adam L. Boxer has authored 213 papers receiving a total of 11.4k indexed citations (citations by other indexed papers that have themselves been cited), including 99 papers in Neurology, 91 papers in Physiology and 77 papers in Psychiatry and Mental health. Recurrent topics in Adam L. Boxer's work include Alzheimer's disease research and treatments (85 papers), Parkinson's Disease Mechanisms and Treatments (71 papers) and Dementia and Cognitive Impairment Research (60 papers). Adam L. Boxer is often cited by papers focused on Alzheimer's disease research and treatments (85 papers), Parkinson's Disease Mechanisms and Treatments (71 papers) and Dementia and Cognitive Impairment Research (60 papers). Adam L. Boxer collaborates with scholars based in United States, United Kingdom and Canada. Adam L. Boxer's co-authors include Bruce L. Miller, Janice B. Schwartz, Dimitrios Kapogiannis, Edward J. Goetzl, Erin L. Abner, Howard J. Rosen, Joel H. Kramer, Ronald C. Petersen, William W. Seeley and Gil D. Rabinovici and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Adam L. Boxer

197 papers receiving 11.2k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Criteria for the diagnosis of corticobasal degeneration

2013 1.2k citations Irene Litvan, Anthony E. Lang et al. Neurology profile →
Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case‐control study

2014 726 citations Adam L. Boxer, Bruce L. Miller et al. Alzheimer s & Dementia profile →
Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease

2015 357 citations Adam L. Boxer, Bruce L. Miller et al. Neurology profile →
The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's disease

2022 307 citations Adam L. Boxer, Gil D. Rabinovici et al. Alzheimer s & Dementia profile →
Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity

2021 163 citations Joel H. Kramer, Adam L. Boxer et al. JAMA Neurology profile →
Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease

2021 154 citations Salvatore Spina, Renaud La Joie et al. Brain profile →
Accelerating Alzheimer’s therapeutic development: The past and future of clinical trials

2023 103 citations Adam L. Boxer et al. profile →

Peers

Countries citing papers authored by Adam L. Boxer

Since Specialization

Citations

This map shows the geographic impact of Adam L. Boxer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adam L. Boxer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adam L. Boxer more than expected).

Fields of papers citing papers by Adam L. Boxer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adam L. Boxer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adam L. Boxer. The network helps show where Adam L. Boxer may publish in the future.

Co-authorship network of co-authors of Adam L. Boxer

This figure shows the co-authorship network connecting the top 25 collaborators of Adam L. Boxer. A scholar is included among the top collaborators of Adam L. Boxer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adam L. Boxer. Adam L. Boxer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Combining plasma neurofilament light chain and frontotemporal atrophy improves differentiation of bvFTD from primary psychiatric disorders 2025 ·Alzheimer s & Dementia ·(unknown), Ashlin R. K. Roy, (unknown), (unknown), Argentina Lario Lago, Yann Cobigo, Julio C. Rojas, Salvatore Spina, Lea T. Grinberg, Katherine P. Rankin, Adam L. Boxer, Andrew D. Krystal, R. Scott Mackin, Joel H. Kramer, Bruce L. Miller, William W. Seeley, Howard J. Rosen, Lawren VandeVrede, David C. Perry	0
2	Challenges and opportunities for novel combination therapies in Alzheimer's disease: a report from the EU/US CTAD Task Force 2025 ·The Journal of Prevention of Alzheimer s Disease ·Davide Angioni, Lefkos Middleton, Randall J. Bateman, Paul Aisen, Adam L. Boxer, (unknown), Jing Zhou, Irene Gerlach, Rema Raman, Howard Fillit, Stephen Salloway, Reisa Sperling, Bruno Vellas, (unknown)	2
3	Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials 2024 ·Movement Disorders ·Andrea Quattrone, Nicolai Franzmeier, Hans‐Jürgen Huppertz, Martin Klietz, Sebastian Niclas Roemer, Adam L. Boxer, Johannes Levin, Günter U. Höglinger, (unknown)	9
4	GPR37 processing in neurodegeneration: a potential marker for Parkinson’s Disease progression rate 2024 ·npj Parkinson s Disease ·(unknown), (unknown), Marc López‐Cano, (unknown), (unknown), Víctor Fernández‐Dueñas, Ana B. Muñoz‐Manchado, Ester Aso, Adam L. Boxer, Pol Andrés‐Benito, Per Svenningsson, Francisco Ciruela	4
5	Montreal cognitive assessment as a cognitive outcome measure in progressive supranuclear palsy 2024 ·Frontiers in Neurology ·(unknown), (unknown), Christopher D. Stephen, (unknown), Marian L. Dale, Douglas Gunzler, Ece Bayram, Tao Xie, Alexander Pantelyat, Leila Montaser‐Kouhsari, Indira García‐Cordero, Maria Carmela Tartaglia, Anthony E. Lang, Matthew Swan, Adam L. Boxer, Lawrence I. Golbe, Anne‐Marie Wills	1
6	Concomitant Medications for Progressive Supranuclear Palsy 2024 ·JAMA Neurology ·(unknown), Douglas Gunzler, Anthony E. Lang, Lawrence I. Golbe, Alexander Pantelyat, Adam L. Boxer, Anne‐Marie Wills, (unknown)	0
7	Unobtrusive In‐Home Digital Monitoring of Frontotemporal Dementia: Feasibility and Adherence 2023 ·Alzheimer s & Dementia ·(unknown), Emily W. Paolillo, Zachary Beattie, Chao‐Yi Wu, (unknown), (unknown), Hilary W. Heuer, Leah K. Forsberg, (unknown), Kelsey A. Holiday, Mario F. Mendez, Bradley F. Boeve, Adam L. Boxer, Jeffrey Kaye, Howard J. Rosen, Adam M. Staffaroni	1
8	Frontotemporal lobar degeneration 2023 ·Nature Reviews Disease Primers ·Murray Grossman, William W. Seeley, Adam L. Boxer, Argye E. Hillis, David S. Knopman, (unknown), Bruce L. Miller, Olivier Piguet, Rosa Rademakers, Jennifer L. Whitwell, Henrik Zetterberg, John C. van Swieten	70
9	A data-driven model of brain volume changes in progressive supranuclear palsy 2022 ·Brain Communications ·William J. Scotton, Martina Bocchetta, Emily Todd, David M. Cash, Neil P. Oxtoby, (unknown), Hilary W. Heuer, Daniel C. Alexander, James B. Rowe, Huw R. Morris, Adam L. Boxer, Jonathan D. Rohrer, P. A. Wijeratne	17
10	A Modified Progressive Supranuclear Palsy Rating Scale for Virtual Assessments 2022 ·Movement Disorders ·Anne‐Marie Wills, Alexander Pantelyat, Alberto J. Espay, James Chan, Irene Litvan, Tao Xie, Marian L. Dale, Steven A. Gunzler, Maria Carmela Tartaglia, Susan H. Fox, Federico Rodríguez‐Porcel, (unknown), Anthony E. Lang, Adam L. Boxer, (unknown), (unknown)	10
11	Comorbid neuropathological diagnoses in early versus late-onset Alzheimer’s disease breakdown → 2021 ·Brain ·Salvatore Spina, Renaud La Joie, Cathrine Petersen, Amber Nolan, (unknown), Celica Cosme, (unknown), Jihye Hwang, Zachary Miller, Eric J. Huang, Anna M. Karydas, Harli Grant, Adam L. Boxer, Maria Luisa Gorno‐Tempini, Howard J. Rosen, Joel H. Kramer, Bruce L. Miller, William W. Seeley, Gil D. Rabinovici, Lea T. Grinberg	154
12	Genetic pleiotropy and the shared pathological features of corticobasal degeneration and progressive supranuclear palsy: a case report and a review of the literature 2021 ·Neurocase ·(unknown), Breton M. Asken, Ethan G. Geier, Katherine P. Rankin, Joel H. Kramer, Adam L. Boxer, Bruce L. Miller, Jennifer S. Yokoyama, Salvatore Spina	3
13	Lower White Matter Volume and Worse Executive Functioning Reflected in Higher Levels of Plasma GFAP among Older Adults with and Without Cognitive Impairment 2021 ·Journal of the International Neuropsychological Society ·Breton M. Asken, Lawren VandeVrede, Julio C. Rojas, Corrina Fonseca, Adam M. Staffaroni, Fanny M. Elahi, Cutter A. Lindbergh, Alexandra C. Apple, Michelle You, (unknown), (unknown), Nicole Fernandes, Adam L. Boxer, Bruce L. Miller, Howie Rosen, Joel H. Kramer, Kaitlin B. Casaletto	25
14	Longitudinal structural and metabolic changes in frontotemporal dementia 2020 ·Neurology ·Alexandre Bejanin, (unknown), Gabe Marx, Yann Cobigo, Leonardo Iaccarino, John Kornak, Adam M. Staffaroni, Bradford C. Dickerson, Bradley F. Boeve, David S. Knopman, (unknown), Bruce L. Miller, William J. Jagust, Adam L. Boxer, Howard J. Rosen, Gil D. Rabinovici	39
15	Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy 2020 ·Molecular Neurodegeneration ·Xu Chen, Yaqiao Li, Chao Wang, Yinyan Tang, Sue‐Ann Mok, Richard Tsai, Julio C. Rojas, Anna Karydas, Bruce L. Miller, Adam L. Boxer, Jason E. Gestwicki, Michelle R. Arkin, Ana María Cuervo, Li Gan	75
16	Plasma neurofilament light chain predicts disease progression in asymptomatic genetic frontotemporal dementia (P5.1-007) 2019 ·Neurology ·(unknown), Ping Wang, Adam M. Staffaroni, Yann Cobigo, Amy Wolf, Hilary W. Heuer, Jamie Fong, Joanne Taylor, Andreas Jeromin, Howard J. Rosen, Bradley F. Boeve, Adam L. Boxer	1
17	Review: Fluid biomarkers for frontotemporal dementias 2018 ·Neuropathology and Applied Neurobiology ·Henrik Zetterberg, John C. van Swieten, Adam L. Boxer, Jonathan D. Rohrer	33
18	Therapy and clinical trials in frontotemporal dementia: past, present, and future 2016 ·Journal of Neurochemistry ·Richard Tsai, Adam L. Boxer	87
19	Plasma Neurofilament Light Chain Predicts Progression in Progressive Supranuclear Palsy (S39.005) 2016 ·Neurology ·(unknown), Anna Karydas, Jee Bang, Richard Tsai, Kaj Blennow, Victor Liman, Joel H. Kramer, Howard J. Rosen, Bruce L. Miller, Henrik Zetterberg, Adam L. Boxer	2
20	Oxytocin for frontotemporal dementia 2014 ·Neurology ·Elizabeth Finger, Julia MacKinley, Mervin Blair, Lindsay D. Oliver, Sarah Jesso, Maria Carmela Tartaglia, Michael Borrie, Jennie Wells, Isabel Dziobek, Stephen Pasternak, Derek Mitchell, Katherine P. Rankin, Andrew Kertesz, Adam L. Boxer	74

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact